Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
2.
Braz. j. med. biol. res ; 48(7): 654-664, 07/2015. graf
Article in English | LILACS | ID: lil-751344

ABSTRACT

Recent evidence indicates that a deficiency of 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) may influence asthma pathogenesis; however, its roles in regulating specific molecular transcription mechanisms remain unclear. We aimed to investigate the effect of 1,25(OH)2D3 on the expression and enzyme activity of histone deacetylase 2 (HDAC2) and its synergistic effects with dexamethasone (Dx) in the inhibition of inflammatory cytokine secretion in a rat asthma model. Healthy Wistar rats were randomly divided into 6 groups: control, asthma, 1,25(OH)2D3 pretreatment, 1,25(OH)2D3 treatment, Dx treatment, and Dx and 1,25(OH)2D3 treatment. Pulmonary inflammation was induced by ovalbumin (OVA) sensitization and challenge (OVA/OVA). Inflammatory cells and cytokines in the bronchoalveolar lavage (BAL) fluid and histological changes in lung tissue were examined. Nuclear factor kappa B (NF-κB) p65 and HDAC2 expression levels were assessed with Western blot analyses and quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Enzyme activity measurements and immunohistochemical detection of HDAC2 were also performed. Our data demonstrated that 1,25(OH)2D3 reduced the airway inflammatory response and the level of inflammatory cytokines in BAL. Although NF-κB p65 expression was attenuated in the pretreatment and treatment groups, the expression and enzyme activity of HDAC2 were increased. In addition, 1,25(OH)2D3 and Dx had synergistic effects on the suppression of total cell infusion, cytokine release, and NF-κB p65 expression, and they also increased HDAC2 expression and activity in OVA/OVA rats. Collectively, our results indicated that 1,25(OH)2D3 might be useful as a novel HDAC2 activator in the treatment of asthma.


Subject(s)
Animals , Male , Asthma/drug therapy , Calcitriol/pharmacology , /drug effects , NF-kappa B/drug effects , Vitamins/pharmacology , Asthma/chemically induced , Blotting, Western , Bronchoalveolar Lavage Fluid/chemistry , Cell Count , Calcitriol/therapeutic use , Cytokines/analysis , Cytokines/drug effects , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation, Enzymologic/drug effects , /metabolism , Immunohistochemistry , Lung/chemistry , Lung/drug effects , NF-kappa B/analysis , Ovalbumin , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reproducibility of Results , Treatment Outcome , Vitamins/therapeutic use
3.
Braz. j. med. biol. res ; 46(12): 1047-1055, dez. 2013. graf
Article in English | LILACS | ID: lil-695976

ABSTRACT

To understand the pathophysiological mechanisms of pulmonary arterial smooth muscle cell (PASMC) proliferation and extracellular-matrix accumulation in the development of pulmonary hypertension and remodeling, this study determined the effects of different doses of adrenomedullin (ADM) and adrenotensin (ADT) on PASMC proliferation and collagen synthesis. The objective was to investigate whether extracellular signal-regulated kinase (ERK1/2) signaling was involved in ADM- and ADT-stimulated proliferation of PASMCs in 4-week-old male Wistar rats (body weight: 100-150 g, n=10). The proliferation of PASMCs was examined by 5-bromo-2-deoxyuridine incorporation. A cell growth curve was generated by the Cell Counting Kit-8 method. Expression of collagen I, collagen III, and phosphorylated ERK1/2 (p-ERK1/2) was evaluated by immunofluorescence. The effects of different concentrations of ADM and ADT on collagen I, collagen III, and p-ERK1/2 protein expression were determined by immunoblotting. We also investigated the effect of PD98059 inhibition on the expression of p-ERK1/2 protein by immunoblotting. ADM dose-dependently decreased cell proliferation, whereas ADT dose-dependently increased it; and ADM and ADT inhibited each other with respect to their effects on the proliferation of PASMCs. Consistent with these results, the expression of collagen I, collagen III, and p-ERK1/2 in rat PASMCs decreased after exposure to ADM but was upregulated after exposure to ADT. PD98059 significantly inhibited the downregulation by ADM and the upregulation by ADT of p-ERK1/2 expression. We conclude that ADM inhibited, and ADT stimulated, ERK1/2 signaling in rat PASMCs to regulate cell proliferation and collagen expression.

4.
Neurol India ; 2003 Dec; 51(4): 528-30
Article in English | IMSEAR | ID: sea-120387

ABSTRACT

Baló's Concentric sclerosis (BCS) is a rare demyelinating disease considered to be a variant of multiple sclerosis (MS). The typical magnetic resonance imaging (MRI) changes associated with BCS consist of concentric rings or onions' cross-section on T1-weighted (T1W) images. Because MRI reveals pathological changes consistent with autopsy in the focus of BCS, it plays an important role in the before-death diagnosis of BCS. We report three cases of BCS diagnosed antemortem on the basis of the typical concentric rings pattern on MRI and on the basis of clinical findings and cerebrospinal fluid (CSF) examination. BCS often occurs in the prime of life, acutely or subacutely. Then come cerebral multifocal symptoms and signs. We find that BCS is not always an acute and irreversible pathological process as described in the past.


Subject(s)
Adult , Diffuse Cerebral Sclerosis of Schilder/pathology , Female , Humans , Magnetic Resonance Imaging , Male , Tomography, X-Ray Computed
5.
Article in English | IMSEAR | ID: sea-21012

ABSTRACT

The first clinical trial of a DNA vaccine designed to protect against malaria has just commenced. This vaccine has been designed to induce protective CD8+ T cell responses against Plasmodium falciparum infected hepatocytes. Herein, we review the rationale behind the development of vaccines that induce protective CD8+ T cells, the strategy for the development of a DNA vaccine designed to protect against falciparum malaria, and the experimental data in rodent models and nonhuman primates which has provided the foundation for trials of DNA vaccines against P. falciparum malaria in humans.


Subject(s)
Animals , Forecasting , Humans , Malaria Vaccines , Malaria, Falciparum/prevention & control , Plasmodium falciparum , Vaccines, DNA
6.
Acta andin ; 4(2): 143-8, 1995. tab
Article in English | LILACS | ID: lil-187064

ABSTRACT

En China, las altiplanicies de Qinghai en el Tibet son las más altas del mundo, y en ellas residen los tibetianos nativos y los inmigrantes chinos (Han). Este artículo se ocupa de las enfermedades producidas por la altura. Existen tres problemas serios producidos por la altura. Primero, el edema pulmonar de altura (HAPE); se observa una alta incidencia de HAPE en los recién llegados a la altura, y por el contrario una menor incidencia en los nativos de altura que reascienden a ella, lo que difiere con los reportes en Norte América y en los Andes. Segundo, la enfermedad cardiaca de altura (HAHD). Los niños y los infantes son los que se encuentran especialmente en riesgo. La mayoría de infantes afectados por esta enfermedad son de origen Han, y presentan insuficiencia cardiaca congestiva severa debido a hipertension pulmonar dentro de los pocos meses de nacido o de arribo a la altura. Las autopsias muestran una hipertrofia ventricular derecha y un engrosamiento de la muscular de las arterias pulmonares periféricas. La mortalidad en promedio fue de 15 por ciento, tal que la HAHD infantil es una emfermedad fatal. Tercero, la enfermedad de Monge o mal de Montaña Crónico (CMS). En los indígenas tibetianos se han observado 15 casos de CMS entre 1991-1993. Los datos epidemiológicos y clínicos muestran que la CMS existe en la altiplanicie de Qinghai-Tibet.


Subject(s)
Humans , Altitude , Altitude Sickness/ethnology , Heart Failure/etiology , Altitude Sickness/epidemiology , Altitude Sickness/etiology , Altitude Sickness/physiopathology , Heart Failure/diagnosis , Pulmonary Edema/epidemiology , Pulmonary Edema/etiology , Pulmonary Edema/pathology
7.
Southeast Asian J Trop Med Public Health ; 1992 Sep; 23(3): 514-9
Article in English | IMSEAR | ID: sea-31891

ABSTRACT

The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.7%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.


Subject(s)
Acute Disease , Adult , Aged , Arthritis, Infectious/drug therapy , Bacteremia/drug therapy , Female , Fleroxacin/adverse effects , Humans , Male , Middle Aged , Osteomyelitis/drug therapy , Prospective Studies , Remission Induction , Taiwan/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL